Literature DB >> 8861917

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

J L Kim1, K A Morgenstern, C Lin, T Fox, M D Dwyer, J A Landro, S P Chambers, W Markland, C A Lepre, E T O'Malley, S L Harbeson, C M Rice, M A Murcko, P R Caron, J A Thomson.   

Abstract

An estimated 1% of the global human population is infected by hepatitis C viruses (HCVs), and there are no broadly effective treatments for the debilitating progression of chronic hepatitis C. A serine protease located within the HCV NS3 protein processes the viral polyprotein at four specific sites and is considered essential for replication. Thus, it emerges as an attractive target for drug design. We report here the 2.5 angstrom resolution X-ray crystal structure of the NS3 protease domain complexed with a synthetic NS4A activator peptide. The protease has a chymotrypsin-like fold and features a tetrahedrally coordinated metal ion distal to the active site. The NS4A peptide intercalates within a beta sheet of the enzyme core.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861917     DOI: 10.1016/s0092-8674(00)81351-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  174 in total

1.  Structural similarities and differences in Staphylococcus aureus exfoliative toxins A and B as revealed by their crystal structures.

Authors:  A C Papageorgiou; L R Plano; C M Collins; K R Acharya
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

2.  Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

Authors:  G Barbato; D O Cicero; F Cordier; F Narjes; B Gerlach; S Sambucini; S Grzesiek; V G Matassa; R De Francesco; R Bazzo
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

3.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.

Authors:  S Orrù; F Dal Piaz; A Casbarra; G Biasiol; R De Francesco; C Steinkühler; P Pucci
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

Review 5.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.

Authors:  Y L Khu; E Koh; S P Lim; Y H Tan; S Brenner; S G Lim; W J Hong; P Y Goh
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 7.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

8.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

9.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

10.  Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey.

Authors:  Esra Yildiz; Asli Oztan; Funda Sar; Ergun Pinarbasi; Rengul Cetin-Atalay; Hikmet Akkiz; Mehmet Ozturk
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.